Search

everythinglearnresearchcommunity

for

Search:↓

LagRag revived their hair using finasteride, minoxidil, derma rolling, dermapen, and biotin shampoo. Users discussed the effectiveness and requested photos with different hair positions.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

User "mynameisbogus" shares 2-month progress using Dut, Min, Oral Min, Keto, Dermarolling, and Retinol for hair loss at age 40. Others discuss impressive results and potential for full hair regrowth.

The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.

A custom-made serum based on double-blind studies for AGA, which includes natural ingredients such as rosemary oil, procyanidin B-2, saw palmetto extract, curcuma aeruginosa, pumpkin seed oil and castor oil. The user has updated their recipe to include apple poly procyanidin B-2 4% concentration and other ingredients before topping it off with Pura d'or serum.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A user shared their impressive hair regrowth progress after 5 months using 1mg oral finasteride every other day, 2.5mg oral minoxidil daily, weekly dermastamping, and daily scalp massages. They reported no side effects and began seeing improvement after 2.5 months.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

This post and conversation are about using receipt paper as a satirical treatment for hair loss. Users humorously discuss various absurd methods, including rubbing, ingesting, and making suppositories out of receipts.

A user's 8-month progress with Fin/Min/Dermarolling treatments for hair loss, which have resulted in great improvements to the user's temples.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

User shares progress after 4 months of using finasteride and dermarolling, with occasional use of coconut and rosemary oil. They aim to stop hair loss and hope for increased top density.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A user's progress with treating their hair loss, including using finasteride, minoxidil, retinoic acid, dermapenning twice weekly and ket 2% shampoo two to three times per week. Other users offered advice such as not derma penning too often or shaving the area bald for a couple of months.

The conversation humorously discusses the journey of deciding to use finasteride for hair loss, with a focus on a funny Facebook post. It also touches on the idea of promoting finasteride use to future generations.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.